No Data
Carl Hansen Buys Handful Of Shares In AbCellera Biologics
AbCellera to Present at Upcoming Investor Conferences in September
AbCellera Biologics Inc. (ABCL): A Top Contender Among Canada's Best Penny Stocks in 2024
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating
KeyBanc analyst Scott Schoenhaus maintains $AbCellera Biologics(ABCL.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.7% and a total average return of -2.9%
KeyBanc Keeps Their Buy Rating on AbCellera Biologics (ABCL)
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday